Abeona Therapeutics Inc [ABEO] stock is trading at $6.75, up 2.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABEO shares have gain 14.02% over the last week, with a monthly amount glided 12.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on March 05, 2025, and set its price target to $16. On July 03, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $15 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $21 on May 30, 2024. Cantor Fitzgerald upgraded its rating to a Overweight but $4 remained the price target by the analyst firm on November 11, 2020. B. Riley FBR started tracking with a Buy rating for this stock on September 18, 2020, and assigned it a price target of $5. In a note dated February 10, 2020, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Abeona Therapeutics Inc [ABEO] stock has fluctuated between $3.93 and $7.32 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $6.75 at the most recent close of the market. An investor can expect a potential return of 166.67% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.86 and Total Capital is -0.86. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Abeona Therapeutics Inc’s Current Ratio is 4.90. On the other hand, the Quick Ratio is 4.90, and the Cash Ratio is 0.89.
Transactions by insiders
Recent insider trading involved Silverstein Christine Berni, Director, that happened on Jul 09 ’25 when 13093.0 shares were sold. Chief Executive Officer, Seshadri Vishwas completed a deal on Jul 09 ’25 to sell 69420.0 shares. Meanwhile, Chief Financial Officer Vazzano Joseph Walter sold 25411.0 shares on Jul 09 ’25.
